MGNX

Over the past six months, MacroGenics experienced several stock-impacting events: a study pause due to safety issues in February 2026; the reporting of 2025 financial results and data disclosure timelines in March 2026; the FDA lifting a hold on a gynecological cancer treatment trial in April 2026; a +20.6% stock movement following increased revenue and a narrowed net loss in its Q1 2026 earnings report in May 2026; a $24.5 million payment from Sanofi for a regulatory milestone in June 2026; the completion of the sale of GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million in July 2026; a -7.7% stock movement after a Phase 1 clinical update for MGC026 indicated a Stage 1 response threshold was achieved and enrollment advanced to Stage 2 in July 2026; a $10 million milestone payment from Gilead Sciences for licensing a preclinical bispecific program in August 2026; Q2 2026 financial results reporting a streamlined operating model and strengthened financial position, with earnings beating consensus in August 2026; news highlighting the stock outpacing medical peers in August 2026; and participation in the H.C. Wainwright 28th Annual Global Investment Conference announced in September 2026. Over the past year, MacroGenics' stock price increased by 117.14%, trading between a low of $1.29 and a high of $5.08.